JP2022546806A5 - - Google Patents
Info
- Publication number
- JP2022546806A5 JP2022546806A5 JP2022513248A JP2022513248A JP2022546806A5 JP 2022546806 A5 JP2022546806 A5 JP 2022546806A5 JP 2022513248 A JP2022513248 A JP 2022513248A JP 2022513248 A JP2022513248 A JP 2022513248A JP 2022546806 A5 JP2022546806 A5 JP 2022546806A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- group
- tumor
- independently
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025115718A JP2025148436A (ja) | 2019-09-04 | 2025-07-09 | 癌免疫療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019903262A AU2019903262A0 (en) | 2019-09-04 | Cancer immunotherapy | |
| AU2019903262 | 2019-09-04 | ||
| AU2019904864A AU2019904864A0 (en) | 2019-12-20 | Cancer immunotherapy (2) | |
| AU2019904864 | 2019-12-20 | ||
| PCT/AU2020/050932 WO2021042171A1 (en) | 2019-09-04 | 2020-09-04 | Cancer immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025115718A Division JP2025148436A (ja) | 2019-09-04 | 2025-07-09 | 癌免疫療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022546806A JP2022546806A (ja) | 2022-11-09 |
| JP2022546806A5 true JP2022546806A5 (cg-RX-API-DMAC7.html) | 2023-09-12 |
Family
ID=74851930
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513248A Pending JP2022546806A (ja) | 2019-09-04 | 2020-09-04 | 癌免疫療法 |
| JP2025115718A Pending JP2025148436A (ja) | 2019-09-04 | 2025-07-09 | 癌免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025115718A Pending JP2025148436A (ja) | 2019-09-04 | 2025-07-09 | 癌免疫療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230043518A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4025204A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022546806A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114364378A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020340468B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021042171A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2811957C (en) | 2010-09-22 | 2019-04-16 | The University Of Melbourne | Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents |
| IL275360B2 (en) | 2017-12-21 | 2023-10-01 | Axelia Oncology Pty Ltd | Optimal compounds |
| NZ783377A (en) | 2019-06-26 | 2026-03-27 | Ena Respiratory Pty Ltd | Pegylated novel molecules for agonising tlr2 |
| WO2021042174A1 (en) * | 2019-09-04 | 2021-03-11 | Ena Therapeutics Pty Ltd | Cancer treatment |
| WO2023154799A1 (en) | 2022-02-14 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy for treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004100965A1 (ja) * | 2003-05-15 | 2004-11-25 | Japan Science And Technology Agency | 免疫刺激剤 |
| GB0907989D0 (en) * | 2009-05-08 | 2009-06-24 | Hybrid Systems Ltd | Multivalent adjuvant display |
| CA2811957C (en) * | 2010-09-22 | 2019-04-16 | The University Of Melbourne | Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents |
| IN2014CN02581A (cg-RX-API-DMAC7.html) * | 2011-10-06 | 2015-08-07 | Immunovaccine Technologies Inc | |
| EP3328418A1 (en) * | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| EP3429618B1 (en) * | 2016-03-16 | 2024-02-21 | Amal Therapeutics SA | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
| AU2018241248B2 (en) * | 2017-03-31 | 2025-01-23 | Ena Respiratory Pty Ltd | Treatment of respiratory infection with a TLR2 agonist |
| IL275360B2 (en) * | 2017-12-21 | 2023-10-01 | Axelia Oncology Pty Ltd | Optimal compounds |
-
2020
- 2020-09-04 JP JP2022513248A patent/JP2022546806A/ja active Pending
- 2020-09-04 WO PCT/AU2020/050932 patent/WO2021042171A1/en not_active Ceased
- 2020-09-04 CN CN202080061095.1A patent/CN114364378A/zh active Pending
- 2020-09-04 US US17/640,704 patent/US20230043518A1/en active Pending
- 2020-09-04 EP EP20860787.9A patent/EP4025204A4/en active Pending
- 2020-09-04 CN CN202511778268.2A patent/CN121371186A/zh active Pending
- 2020-09-04 AU AU2020340468A patent/AU2020340468B2/en active Active
-
2025
- 2025-07-09 JP JP2025115718A patent/JP2025148436A/ja active Pending